Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Start Date
6/21/2023
Completion Date
3/1/2028
Summary
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Detailed Description
This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).
Eligibility Criteria
Age Range: 60 years to No maximum
Interventions
VOY-101
Conditions
Locations
Retina Macula Institute of AZ
Scottsdale, Arizona 85255
United States
The Retina Partners
Encino, California 91436
United States
Retinal Consultants Medical Group
Sacramento, California 95825
United States
Retina Consultants San Diego
San Diego, California 92064
United States
Star Retina
Burleson, Texas 76028
United States
Retina Center of Texas
Southlake, Texas 76092
United States
University of Utah John A. Moran Eye Center
Salt Lake City, Utah 84132
United States
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales 2000
Australia
Cerulea Clinical Trials
East Melbourne, Victoria 3002
Australia
Rambam Medical Center
Haifa,
Israel
Tel-Aviv Sourasky Medical Center, Ophthalmology Division
Tel Aviv, 64239
Israel